|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:antidote
|
gptkb:andexanet_alfa
|
|
gptkbp:approvalYear
|
2011
2012
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:FDA
gptkb:EMA
gptkb:TGA
|
|
gptkbp:ATCCode
|
B01AF02
|
|
gptkbp:bioavailability
|
~50%
|
|
gptkbp:CASNumber
|
503612-47-3
|
|
gptkbp:chemicalFormula
|
C25H25N5O4
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hepatic impairment
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:eliminationHalfLife
|
~12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
5 mg
2.5 mg
|
|
gptkbp:genericName
|
gptkb:apixaban
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eliquis
|
|
gptkbp:indication
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of recurrent DVT and PE
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:India
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
factor Xa inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2J2)
|
|
gptkbp:molecularWeight
|
459.5 g/mol
|
|
gptkbp:patentExpired
|
2026 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
B (Australia)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:proteinBinding
|
87%
|
|
gptkbp:riskFactor
|
risk of spinal/epidural hematoma
increased bleeding with other anticoagulants
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
|
|
gptkbp:bfsParent
|
gptkb:apixaban
gptkb:Bristol_Myers_Squibb
gptkb:BMS
gptkb:百时美施贵宝
gptkb:Bristol-Myers_Squibb
gptkb:NYSE:PFE
|
|
gptkbp:bfsLayer
|
6
|